Pirfenidone Tablet, Film Coated
Product Images NDC 42571-335

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 42571-335). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Micro Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pirfenidone-267mg-lbl.jpg (Pirfenidone 267mg Lbl)

Each tablet of this medication contains 267 mg of pirfenidone, and the NDC number is 42571-335-90. The usual dosage and administration information can be found in the package insert. The medication should be stored at a temperature of 25°C (77°F) with excursions allowed between 15° to 30°C (59° to 86°F) in accordance with USP Controlled Room Temperature guidelines. The medication is for prescription use only and should be kept out of reach of children. This medication is manufactured for Micro Labs USA, Inc. with a production date of rev.02/2022.*

FDA Label Image

Pirfenidone-801mg-lbl.jpg (Pirfenidone 801mg Lbl)

This is a description of a medication containing pirfenidone with a dosage of 801mg per tablet. The directions for the dosage and administration information can be found on the package insert. The tablets should be stored between 15° to 30°C (59° to 86°F). The medication is manufactured by Micro Labs USA, Inc. and comes in a bottle of 90 tablets. This medication is only available through a prescription and should be kept out of reach of children. The text does not provide complete information about the medicine's purpose or indications.*

FDA Label Image

Figure 1 (Pirfenidone Figure1)

This appears to be a table showing the percentage of patients experiencing worsening or improving lung function (measured by FVC or forced vital capacity) after taking either pirfenidone or a placebo over a period of 52 weeks. The numbers in parentheses seem to indicate the number of patients in each group. More information is needed to fully understand the context and purpose of this table.*

FDA Label Image

Figure 2 (Pirfenidone Figure2)

FDA Label Image

Figure 3 (Pirfenidone Figure3)

FDA Label Image

Structure (Pirfenidone Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.